NEW YORK, Dec. 22, 2020 /PRNewswire/ — Infor today announced a global strategic partnership with MphRx to help healthcare organizations drive vaccine management for the novel Coronavirus. Even though the United States has advanced to the vaccination phase, new challenges present themselves, which this partnership hopes to solve. COVID-19 vaccines are complex deployments for health organizations, requiring management of multiple-dose delivery and symptom monitoring. It is critical that health systems implement vaccine management solutions to ensure patient health through this crisis and remediation. This applies to pharmaceutical manufacturers, governmental healthcare, hospitals, life-sciences organizations, pharmacies, and payers.

Healthcare organizations are challenged to aggregate data from disparate clinical systems to effectively prioritize and engage patients for innoculation, ensure multi-dose follow-up, monitor adverse effects, measure reinfection rates, and track efficacy. The solution to this is a platform that can deploy in days, delivering powerful vaccine administration combined with effective communication capabilities both into legacy clinical systems as well as modern messaging to patients.

This partnership of Infor and MphRx brings together two best-in-breed platforms to deliver what is critically needed today — an integrated and comprehensive enterprise solution for healthcare organizations to address three main challenges in digital transformation including COVID-19 demands: provide seamless omnichannel patient experience, drive care coordination, and streamline interoperability. Specifically, MphRx’s Minerva aggregates data from across healthcare information systems and transforms it into a single, unified, FHIR-based patient record — a digital pathway to a new world of omnichannel care. Complementing this capability, Infor Cloverleaf Integration Suite streamlines the exchange of clinical data to help improve healthcare outcomes and business operations.

“Healthcare delivery is dynamic, and the pandemic has further accelerated digital transformation in this space. Unfortunately for many organizations, data still lives in different software systems that are often disconnected and create roadblocks in care innovation. The current challenge of vaccinating our entire population is driving us to accelerate solutions to manage real-world healthcare delivery at scale,” said Varun Anand, chief operating officer and co-founder of MphRx. “By jointly offering the Infor Cloverleaf Integration Engine and MphRx’s Minerva, organizations can unlock these data silos and accelerate interoperability and digital transformation across their business. We’re delighted to expand our partner ecosystem with Infor and the synergies between the two companies will allow healthcare organizations leverage our joint solutions to build better and more efficient healthcare delivery experiences for patients and their communities.”

The Infor Cloverleaf-Minerva solution provides a unified health record across the enterprise with Minerva’s vendor-neutral SMART on FHIR repository. It integrates data across disparate sources of healthcare data using Infor’s Cloverleaf Integration Suite and deploys out-of-the-box clinical web and mobile applications. These empower healthcare professionals with a 360-degree view of their patients across the care continuum, regardless of the clinical settings in which their information was recorded, and Minerva will streamline workflows to expedite and aid informed decision-making among the caregivers to deliver seamless omnichannel care. 

Users can launch white-label, out-of-the-box web and mobile-based patient applications to provide consumers and their family members with real-time access to their records, schedule appointments, access omnichannel virtual care services, gain access to personalized care and make payments. Simultaneously, providing partners, third parties and consumers real-time and secure access to data using the SMART on FHIR framework. There is also an extensible digital toolkit available to customers to drive future innovation based on this unified health record such as automation, artificial intelligence and population health initiatives.

“The COVID-19 pandemic has placed unprecedented demands on healthcare organizations across the world. It is paramount that isolated platforms, clinicians, and patients are connected to meet the critical demands for accelerated vaccination programs,” says Mike Poling, senior vice president of Infor Healthcare. “Infor’s partnership with MphRx empowers healthcare organizations with the platform that deploys in days, delivering powerful vaccine administration, powered by rapid and clear clinical communication throughout the care continuum.”

About MphRx
MphRx is an innovation partner for organizations pioneering the next generation of healthcare. Its platform provides best-in-class interoperability, engagement, and automation solutions that open a new world of virtual care. The company is a rapidly growing healthcare technology organization headquartered in New York City, with offices in Australia, UK, India, Singapore, and Brazil. MphRx is an ISO 13485, ISO 27001 certified organization. This year, Frost and Sullivan awarded a 2020 Global Digital Transformation Platform Enabling Technology Leadership Award to MphRx. Visit https://www.mphrx.com/ 

About Minerva
Minerva is a FHIR-based, vendor-neutral innovation platform from MphRx. Built to empower both patients and enterprises, Minerva takes healthcare organizations beyond digital transformation to a new world of seamless omnichannel care. The platform is deployed in over 20 countries and manages over 460 million patient records with millions of users. Minerva has enabled large health systems to aggregate healthcare data and orchestrates workflows across complex and diverse technology environments using a unique vendor-neutral approach. The platform complies with HIPAA, GDPR, and other global data protection acts. To learn more, visit https://www.mphrx.com/ and follow us on LinkedIn, Twitter and Facebook

About Infor
Infor is a global leader in business cloud software specialized by industry. Providing mission-critical enterprise applications to 67,000 customers in more than 175 countries, Infor software is designed to deliver more value and less risk, with more sustainable operational advantages. We empower our 17,000 employees to leverage their deep industry expertise and use data-driven insights to create, learn and adapt quickly to solve emerging business and industry challenges. Infor is committed to providing our customers with modern tools to transform their business and accelerate their own path to innovation. To learn more, please visit www.infor.com.

For more information:
Christina Ledger
(312) 620-1926
christina.ledger@infor.com

This announcement reflects the direction Infor may take with regard to the specific product(s) described herein, all of which is subject to change by Infor in its sole discretion, with or without notice to you.  This announcement is not a commitment to you in any way and you should not rely on this document or any of its content in making any decision.  Infor is not committing to develop or deliver any specified enhancement, upgrade, product or functionality, even if such is described in this announcement and even if such description is accompanied by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “project,” “predict,” “should,” “will,” and/or similar expressions.  Many factors can affect Infor’s product development plans and the nature, content and timing of future product releases, all of which remain in the sole discretion of Infor.  This announcement, in whole or in part, may not be incorporated into any contractual agreement with Infor or its subsidiaries or affiliates.  Infor expressly disclaims any liability with respect to this announcement.

View original content to download multimedia:http://www.prnewswire.com/news-releases/infor-and-mphrx-announce-global-solution-to-help-healthcare-organizations-manage-covid-19-vaccine-innoculation-with-real-world-clinical-data-301197357.html

SOURCE Infor